|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association between population vitamin D status and SARS-CoV-2 related serious-critical illness and deaths:An ecological integrative approach显示文摘BACKGROUND Vitamin D population status may have possible unappreciated consequences to the coronavirus disease 2019(COVID-19)pandemic.Αsignificant association between vitamin D sufficiency and reduction in clinical severity and inpatient mortality from COVID-19 disease has recently been shown,while a recent study has claimed lower COVID-19 cases in European countries with a better vitamin D status.Low serum 25-hydroxyvitamin-D[25(OH)D]was identified as an independent risk factor for COVID-19 infection and hospitalization,and administration of 0.532 mg(21280 IU)of calcifediol or 25(OH)D,followed by 0.266 mg on days 3 and 7 and then weekly until discharge or intensive care unit admission significantly reduced the need for intensive care unit treatment.AIM To elucidate the role of vitamin D European population status in the COVID-19 pandemic,data from the Worldometer were analyzed.METHODS Linear regression explored the correlation between published representativestandardized population vitamin D concentrations and the number of total cases/million(M),recovered/M,deaths/M and serious-critically ill/M from COVID-19 for 26 European countries populated>4 M(Worldometer).Life expectancy was analyzed with semi-parametric regression.Weighted analysis of variance/analysis of covariance evaluated serious-critical/M and deaths/M by the vitamin D population status:Deficient<50,insufficient:50-62.5,mildly insufficient>62.5-75 and sufficient>75 nmol/L,while controlling for life expectancy for deaths/M.Statistical analyses were performed in XLSTAT LIFE SCIENCE and R(SemiPar Library).RESULTS Linear regression found no correlation between population vitamin D concentrations and the total cases-recovered/M,but negative correlations predicting a reduction of 47%-64%-80%in serious-critical illnesses/M and of 61%-82%-102.4%in deaths/M further enhanced when adapting for life expectancy by 133-177-221%if 25(OH)D concentrations reach 100-125-150 nmol/L,sustained on August 15,2020,indicating a truthful association.Weighted analysis of variance was performed to evaluate serious-critical/M(r2=0.22)by the vitamin D population status and analysis of covariance the deaths/M(r2=0.629)controlling for life expectancy(r2=0.47).Serious-critical showed a decreasing trend(P<0.001)from population status deficient(P<0.001)to insufficient by 9.2%(P<0.001),to mildly insufficient by 47.6%(P<0.044)and to sufficient by 100%(reference,P<0.001).For deaths/M the respective decreasing trend(P<0.001)was 62.9%from deficient(P<0.001)to insufficient(P<0.001),65.15%to mildly insufficient(P<0.001)and 78.8%to sufficient(P=0.041).CONCLUSION Achieving serum 25(OH)D 100-150 nmol/L(40-60 ng/mL)(upper tolerable daily doses followed by maintenance proposed doses not requiring medical supervision,Endocrine Society)may protect from serious-critical illness/death from COVID-19 disease. | Dimitrios T Papadimitriou Alexandros K Vassaras Michael F Holick | 2021 | World Journal of Virology2021，10，3： | 2 |
| 2 | Treatment of alopecia totalis/universalis/focalis with vitamin D and analogs:Three case reports and a literature review显示文摘BACKGROUND Alopecia areata(AA)is an inflammatory disease with autoimmune,environmental,and inherited components directed at the hair follicle,either limited to patchy hair loss over the scalp(Focalis,AF),total loss of scalp hair(Totalis,AT),or total loss of both scalp and body hair(Universalis,AU).Despite multiple treatment modalities,no therapy exists.Vitamin D deficiency in patients with AA/AT/AF influences disease severity and duration,inversely correlating with inflammation histologically.CASE SUMMARY Three girls presented with AT(P1),AU(P2),and AF(P3)at the ages of 1,5,and 5 years,respectively.For P1-P2,all available treatments implemented for 2 years had failed.We started an initial 6-mo repletion with oral cholecalciferol 2000/4000 IU/d,with no apparent effect.Then we attempted immunomodulation using oral calcitriol and its analog paricalcitol.On calcitriol,0.5 mcg/d P1 regrew hair within 6 mo.After 4 years,a relapse with loss of eyebrow hair was resolved after doubling the calcitriol dose to 0.5 mcg×2/d;the results have been maintained for 6 years to date.On calcitriol,0.25 mcg×3/d P2 led to the development of asymptomatic hypercalcemia-hypercalciuria,which was immediately resolved by switching to paricalcitol 2 mcg×3/d;mild tolerable hypercalciuria was maintained.Hair regrowth was observed at 6 mo,stabilizing only as fur at 12 mo.AF in P3 was resolved completely within 3 mo on a daily high dose(8000 IU)of cholecalciferol.CONCLUSION Vitamin D may have immunomodulating therapeutic impact on AT/AU/AF,which needs to be explored with further pilot clinical trials. | Dimitrios T Papadimitriou Christina Bothou Eleni Dermitzaki Alexios Alexopoulos George Mastorakos | 2021 | World Journal of Clinical Pediatrics2021，10，6： | 1 |
| 3 | Rifampicin for COVID-19显示文摘Vaccinations for coronavirus disease-2019(COVID-19)have begun more than a year before,yet without specific treatments available.Rifampicin,critically important for human medicine(World Health Organization’s list of essential medicines),may prove pharmacologically effective for treatment and chemoprophylaxis of healthcare personnel and those at higher risk.It has been known since 1969 that rifampicin has a direct selective antiviral effect on viruses which have their own RNA polymerase(severe acute respiratory syndrome coronavirus 2),like the main mechanism of action of remdesivir.This involves inhibition of late viral protein synthesis,the virion assembly,and the viral polymerase itself.This antiviral effect is dependent on the administration route,with local application resulting in higher drug concentrations at the site of viral replication.This would suggest also trying lung administration of rifampicin by nebulization to increase the drug’s concentration at infection sites while minimizing systemic side effects.Recent in silico studies with a computer-aided approach,found rifampicin among the most promising existing drugs that could be repurposed for the treatment of COVID-19. | George D Panayiotakopoulos Dimitrios T Papadimitriou | 2022 | World Journal of Virology2022，11，2： | 1 |
| 4 | Negativation of type1 diabetes-associated autoantibodies to glutamic acid decarboxylase and insulin in children treated with oral calcitriol显示文摘 | Dimitrios T Papadimitriou Chrisanthi | 2013 | J Diabetes2013，5，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员